Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Copenhagen Prospective Personalized Oncology (CoPPO) - Clinical utility of using molecular profiling to select patients to phase 1 trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{256b4debd4d747778908856fbbaabf90,
title = "Copenhagen Prospective Personalized Oncology (CoPPO) - Clinical utility of using molecular profiling to select patients to phase 1 trials",
abstract = "PURPOSE: We evaluated the clinical benefit of tumor molecular profiling (MP) to select treatment in the phase 1 setting.EXPERIMENTAL DESIGN: Patients with advanced solid cancers and exhausted treatment options referred to a phase 1 unit were included in a prospective single-centre single-arm open-label study (NCT02290522). Tumor biopsies were obtained for comprehensive genomic analysis including whole exome sequencing (WES) and RNA sequencing. When possible, patients were treated with regimen matched to the genomic profile. Primary endpoint was progression free survival.RESULTS: From May 2013 to January 2017 a total of 591 patients were enrolled with 500 patients undergoing biopsy. Genomic profiles were obtained in 460 patients and a potential actionable target was identified in 352 (70{\%}) of 500 biopsied patients. One hundred and one patients (20{\%}) received matched treatment based on either gene mutations or RNA expression levels of targets available in early clinical trials or off-label treatment. Objective response according to RECIST1.1 was observed in 15/101 patients (0{\%} CR, 15{\%} PR) with a median PFS of 12 weeks (95{\%} CI 9.9-14.4).CONCLUSIONS: Our study supports the feasibility of genomic profiling to select patients in the phase 1 setting and suggests that genomic matching can be beneficial for a minor subset of patients with no other treatment options. Randomized studies may validate this assumption.",
author = "Tuxen, {Ida Viller} and Rohrberg, {Kristoffer Staal} and Olga {\O}strup and Ahlborn, {Lise Barlebo} and Schmidt, {Ane Yde} and Iben Spanggaard and Hasselby, {Jane P} and Eric Santoni-Rugiu and Yde, {Christina Westmose} and Morten Mau-Soerensen and Nielsen, {Finn Cilius} and Ulrik Lassen",
note = "{\circledC}2018 American Association for Cancer Research.",
year = "2019",
doi = "10.1158/1078-0432.CCR-18-1780",
language = "English",
volume = "25",
pages = "1239--1247",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research (A A C R)",
number = "4",

}

RIS

TY - JOUR

T1 - Copenhagen Prospective Personalized Oncology (CoPPO) - Clinical utility of using molecular profiling to select patients to phase 1 trials

AU - Tuxen, Ida Viller

AU - Rohrberg, Kristoffer Staal

AU - Østrup, Olga

AU - Ahlborn, Lise Barlebo

AU - Schmidt, Ane Yde

AU - Spanggaard, Iben

AU - Hasselby, Jane P

AU - Santoni-Rugiu, Eric

AU - Yde, Christina Westmose

AU - Mau-Soerensen, Morten

AU - Nielsen, Finn Cilius

AU - Lassen, Ulrik

N1 - ©2018 American Association for Cancer Research.

PY - 2019

Y1 - 2019

N2 - PURPOSE: We evaluated the clinical benefit of tumor molecular profiling (MP) to select treatment in the phase 1 setting.EXPERIMENTAL DESIGN: Patients with advanced solid cancers and exhausted treatment options referred to a phase 1 unit were included in a prospective single-centre single-arm open-label study (NCT02290522). Tumor biopsies were obtained for comprehensive genomic analysis including whole exome sequencing (WES) and RNA sequencing. When possible, patients were treated with regimen matched to the genomic profile. Primary endpoint was progression free survival.RESULTS: From May 2013 to January 2017 a total of 591 patients were enrolled with 500 patients undergoing biopsy. Genomic profiles were obtained in 460 patients and a potential actionable target was identified in 352 (70%) of 500 biopsied patients. One hundred and one patients (20%) received matched treatment based on either gene mutations or RNA expression levels of targets available in early clinical trials or off-label treatment. Objective response according to RECIST1.1 was observed in 15/101 patients (0% CR, 15% PR) with a median PFS of 12 weeks (95% CI 9.9-14.4).CONCLUSIONS: Our study supports the feasibility of genomic profiling to select patients in the phase 1 setting and suggests that genomic matching can be beneficial for a minor subset of patients with no other treatment options. Randomized studies may validate this assumption.

AB - PURPOSE: We evaluated the clinical benefit of tumor molecular profiling (MP) to select treatment in the phase 1 setting.EXPERIMENTAL DESIGN: Patients with advanced solid cancers and exhausted treatment options referred to a phase 1 unit were included in a prospective single-centre single-arm open-label study (NCT02290522). Tumor biopsies were obtained for comprehensive genomic analysis including whole exome sequencing (WES) and RNA sequencing. When possible, patients were treated with regimen matched to the genomic profile. Primary endpoint was progression free survival.RESULTS: From May 2013 to January 2017 a total of 591 patients were enrolled with 500 patients undergoing biopsy. Genomic profiles were obtained in 460 patients and a potential actionable target was identified in 352 (70%) of 500 biopsied patients. One hundred and one patients (20%) received matched treatment based on either gene mutations or RNA expression levels of targets available in early clinical trials or off-label treatment. Objective response according to RECIST1.1 was observed in 15/101 patients (0% CR, 15% PR) with a median PFS of 12 weeks (95% CI 9.9-14.4).CONCLUSIONS: Our study supports the feasibility of genomic profiling to select patients in the phase 1 setting and suggests that genomic matching can be beneficial for a minor subset of patients with no other treatment options. Randomized studies may validate this assumption.

UR - http://www.scopus.com/inward/record.url?scp=85061613357&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-18-1780

DO - 10.1158/1078-0432.CCR-18-1780

M3 - Journal article

VL - 25

SP - 1239

EP - 1247

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -

ID: 55864659